 Edward Janoff
Concepts (572)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Streptococcus pneumoniae | 36 | 2021 | 141 | 5.510 |
Why?
| | HIV-1 | 36 | 2022 | 772 | 4.320 |
Why?
| | HIV Infections | 46 | 2023 | 2454 | 3.760 |
Why?
| | Pneumococcal Infections | 18 | 2021 | 96 | 3.650 |
Why?
| | Antibodies, Bacterial | 25 | 2021 | 124 | 3.390 |
Why?
| | Immunoglobulin G | 35 | 2018 | 785 | 3.320 |
Why?
| | Meningitis, Cryptococcal | 9 | 2023 | 28 | 3.160 |
Why?
| | Immunoglobulin A | 21 | 2022 | 174 | 2.810 |
Why?
| | Pneumococcal Vaccines | 20 | 2021 | 140 | 2.520 |
Why?
| | AIDS-Related Opportunistic Infections | 15 | 2021 | 113 | 2.370 |
Why?
| | Bacterial Vaccines | 16 | 2000 | 60 | 2.040 |
Why?
| | Pneumonia, Pneumococcal | 9 | 2023 | 40 | 1.870 |
Why?
| | B-Lymphocytes | 9 | 2021 | 767 | 1.730 |
Why?
| | Acquired Immunodeficiency Syndrome | 19 | 2014 | 219 | 1.650 |
Why?
| | Milk, Human | 8 | 2015 | 134 | 1.510 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 5 | 2016 | 18 | 1.340 |
Why?
| | Cerebrospinal Fluid | 3 | 2020 | 93 | 1.290 |
Why?
| | Vaccines, Conjugate | 8 | 2021 | 63 | 1.270 |
Why?
| | Lymphocyte Activation | 8 | 2021 | 1062 | 1.210 |
Why?
| | Infectious Disease Transmission, Vertical | 5 | 2015 | 156 | 1.120 |
Why?
| | Serine Endopeptidases | 6 | 2022 | 105 | 1.110 |
Why?
| | Viremia | 2 | 2018 | 127 | 1.070 |
Why?
| | Intestinal Mucosa | 6 | 2015 | 529 | 0.990 |
Why?
| | Immunoglobulin Variable Region | 3 | 2014 | 72 | 0.960 |
Why?
| | Vaccination | 11 | 2021 | 1218 | 0.950 |
Why?
| | Bacterial Capsules | 7 | 2014 | 32 | 0.940 |
Why?
| | Antifungal Agents | 5 | 2023 | 134 | 0.920 |
Why?
| | Adaptive Immunity | 4 | 2021 | 160 | 0.880 |
Why?
| | Diarrhea | 12 | 1997 | 180 | 0.860 |
Why?
| | Streptolysins | 6 | 1998 | 8 | 0.850 |
Why?
| | Pregnancy Complications, Infectious | 3 | 2014 | 296 | 0.850 |
Why?
| | Haemophilus Vaccines | 4 | 2014 | 29 | 0.840 |
Why?
| | Immunity, Innate | 8 | 2016 | 744 | 0.820 |
Why?
| | Penicillin Resistance | 3 | 2017 | 8 | 0.810 |
Why?
| | Polysaccharides, Bacterial | 5 | 2007 | 69 | 0.750 |
Why?
| | Adult | 59 | 2023 | 31324 | 0.750 |
Why?
| | Antibody Affinity | 5 | 2014 | 54 | 0.740 |
Why?
| | Cell Compartmentation | 1 | 2020 | 53 | 0.730 |
Why?
| | Humans | 136 | 2023 | 118251 | 0.730 |
Why?
| | Immunoglobulin M | 12 | 2017 | 251 | 0.680 |
Why?
| | Immunoglobulin D | 2 | 2017 | 28 | 0.670 |
Why?
| | Down Syndrome | 1 | 2023 | 328 | 0.650 |
Why?
| | Breast Feeding | 4 | 2017 | 381 | 0.650 |
Why?
| | Immunity, Humoral | 2 | 2022 | 117 | 0.650 |
Why?
| | Plasma Cells | 3 | 2017 | 59 | 0.640 |
Why?
| | HIV Antibodies | 6 | 2014 | 49 | 0.630 |
Why?
| | Anti-Retroviral Agents | 3 | 2014 | 207 | 0.620 |
Why?
| | Female | 65 | 2023 | 61261 | 0.600 |
Why?
| | Nasal Polyps | 1 | 2017 | 49 | 0.600 |
Why?
| | Serogroup | 1 | 2017 | 34 | 0.590 |
Why?
| | Case-Control Studies | 12 | 2021 | 3156 | 0.580 |
Why?
| | Antibodies, Monoclonal | 6 | 2020 | 1279 | 0.580 |
Why?
| | Neurosurgical Procedures | 1 | 2018 | 164 | 0.580 |
Why?
| | Uganda | 10 | 2017 | 74 | 0.570 |
Why?
| | Sinusitis | 2 | 2017 | 175 | 0.560 |
Why?
| | CD4-Positive T-Lymphocytes | 6 | 2017 | 979 | 0.560 |
Why?
| | Dendritic Cells | 2 | 2016 | 442 | 0.550 |
Why?
| | Rhinitis | 1 | 2017 | 129 | 0.550 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2016 | 139 | 0.550 |
Why?
| | Disease | 1 | 2016 | 87 | 0.550 |
Why?
| | Anti-HIV Agents | 6 | 2016 | 662 | 0.540 |
Why?
| | Haemophilus influenzae type b | 1 | 2014 | 11 | 0.510 |
Why?
| | Antibodies, Neutralizing | 2 | 2013 | 225 | 0.500 |
Why?
| | T-Lymphocytes | 6 | 2018 | 1770 | 0.500 |
Why?
| | Burns | 1 | 2018 | 247 | 0.500 |
Why?
| | Male | 55 | 2023 | 57474 | 0.490 |
Why?
| | Immunoglobulins | 5 | 2007 | 152 | 0.490 |
Why?
| | Giardiasis | 7 | 1990 | 14 | 0.490 |
Why?
| | Giardia | 7 | 1990 | 9 | 0.490 |
Why?
| | Mitochondrial Proteins | 1 | 2016 | 224 | 0.490 |
Why?
| | Metagenome | 2 | 2012 | 120 | 0.490 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2013 | 3 | 0.480 |
Why?
| | Intestines | 3 | 2017 | 330 | 0.480 |
Why?
| | Transmembrane Activator and CAML Interactor Protein | 1 | 2013 | 4 | 0.480 |
Why?
| | Immunoglobulin A, Secretory | 5 | 2011 | 11 | 0.470 |
Why?
| | Bacterial Proteins | 11 | 2019 | 762 | 0.470 |
Why?
| | Antibody Specificity | 7 | 2013 | 182 | 0.460 |
Why?
| | Cryptococcus neoformans | 2 | 2010 | 18 | 0.460 |
Why?
| | Middle Aged | 34 | 2021 | 27510 | 0.450 |
Why?
| | Genitalia, Female | 2 | 2012 | 40 | 0.450 |
Why?
| | Immunocompromised Host | 2 | 2009 | 198 | 0.440 |
Why?
| | Infant, Newborn | 12 | 2023 | 5230 | 0.430 |
Why?
| | Bacterial Adhesion | 3 | 2019 | 79 | 0.420 |
Why?
| | Microbiota | 2 | 2016 | 655 | 0.420 |
Why?
| | Cytotoxins | 4 | 1996 | 16 | 0.410 |
Why?
| | Bacteremia | 3 | 1999 | 161 | 0.400 |
Why?
| | Pneumonia, Bacterial | 3 | 2004 | 110 | 0.380 |
Why?
| | Vagina | 1 | 2012 | 150 | 0.380 |
Why?
| | Mouth Mucosa | 4 | 2011 | 81 | 0.380 |
Why?
| | Antibodies, Fungal | 1 | 2010 | 9 | 0.370 |
Why?
| | Antiviral Agents | 3 | 2009 | 653 | 0.360 |
Why?
| | Viral Load | 6 | 2020 | 406 | 0.350 |
Why?
| | Influenza, Human | 3 | 2009 | 553 | 0.340 |
Why?
| | DNA-Binding Proteins | 1 | 2016 | 1343 | 0.340 |
Why?
| | Amphotericin B | 4 | 2014 | 30 | 0.340 |
Why?
| | HIV Seropositivity | 4 | 1999 | 111 | 0.340 |
Why?
| | Mycoses | 4 | 2014 | 68 | 0.330 |
Why?
| | Aging | 5 | 2010 | 1675 | 0.320 |
Why?
| | Transcription Factors | 1 | 2016 | 1567 | 0.320 |
Why?
| | Influenza Vaccines | 3 | 2009 | 501 | 0.310 |
Why?
| | Immunity, Mucosal | 4 | 2011 | 85 | 0.310 |
Why?
| | Prospective Studies | 12 | 2018 | 6443 | 0.310 |
Why?
| | Lipoproteins, IDL | 1 | 2007 | 1 | 0.310 |
Why?
| | Cohort Studies | 9 | 2023 | 5078 | 0.300 |
Why?
| | Lipoproteins, LDL | 1 | 2007 | 138 | 0.290 |
Why?
| | Infant | 15 | 2017 | 8254 | 0.280 |
Why?
| | Immunologic Memory | 4 | 2017 | 312 | 0.280 |
Why?
| | Antibodies, Protozoan | 4 | 1990 | 28 | 0.270 |
Why?
| | Bacteria | 1 | 2012 | 751 | 0.270 |
Why?
| | Gene Expression | 3 | 2017 | 1482 | 0.270 |
Why?
| | Bacterial Toxins | 3 | 1995 | 105 | 0.270 |
Why?
| | Mutation | 4 | 2014 | 3435 | 0.260 |
Why?
| | Cryptosporidiosis | 3 | 1990 | 11 | 0.260 |
Why?
| | Nose | 3 | 2015 | 58 | 0.260 |
Why?
| | Antibody Formation | 4 | 2016 | 275 | 0.260 |
Why?
| | Aged | 23 | 2021 | 19594 | 0.260 |
Why?
| | Virus Replication | 5 | 2008 | 398 | 0.260 |
Why?
| | Proteins | 3 | 2001 | 935 | 0.250 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2004 | 37 | 0.250 |
Why?
| | Enterotoxins | 2 | 1995 | 86 | 0.240 |
Why?
| | Cytokines | 5 | 2023 | 1880 | 0.240 |
Why?
| | Smallpox | 1 | 2003 | 7 | 0.240 |
Why?
| | Incidence | 2 | 2023 | 2413 | 0.240 |
Why?
| | HIV Seronegativity | 4 | 1995 | 24 | 0.240 |
Why?
| | Diphtheria Toxoid | 3 | 1999 | 12 | 0.240 |
Why?
| | Leukocyte Count | 3 | 2014 | 303 | 0.230 |
Why?
| | Genes, Immunoglobulin | 2 | 2000 | 26 | 0.230 |
Why?
| | Interleukin-15 | 1 | 2023 | 77 | 0.230 |
Why?
| | Young Adult | 8 | 2021 | 10731 | 0.230 |
Why?
| | Chemokines | 2 | 2023 | 228 | 0.230 |
Why?
| | Lipopolysaccharide Receptors | 2 | 2021 | 88 | 0.230 |
Why?
| | Bacterial Infections | 4 | 2016 | 226 | 0.220 |
Why?
| | Somatic Hypermutation, Immunoglobulin | 1 | 2022 | 18 | 0.220 |
Why?
| | Disease Transmission, Infectious | 2 | 2004 | 56 | 0.220 |
Why?
| | Community-Acquired Infections | 3 | 1999 | 142 | 0.210 |
Why?
| | Interleukins | 2 | 2023 | 242 | 0.210 |
Why?
| | Immunoglobulin Heavy Chains | 2 | 2013 | 72 | 0.210 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2015 | 507 | 0.210 |
Why?
| | Enoxaparin | 1 | 2022 | 51 | 0.200 |
Why?
| | Complement System Proteins | 2 | 2007 | 290 | 0.200 |
Why?
| | Biomarkers | 5 | 2021 | 3567 | 0.200 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 1 | 2021 | 9 | 0.200 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 26 | 0.200 |
Why?
| | Vaginal Discharge | 1 | 2001 | 3 | 0.200 |
Why?
| | RNA, Bacterial | 2 | 2012 | 177 | 0.200 |
Why?
| | Interleukin-10 | 2 | 2021 | 304 | 0.200 |
Why?
| | Gastric Mucosa | 1 | 2001 | 45 | 0.200 |
Why?
| | Cryptosporidium | 3 | 1990 | 12 | 0.200 |
Why?
| | Antigens, Protozoan | 3 | 1989 | 19 | 0.190 |
Why?
| | Molecular Sequence Data | 4 | 2013 | 2855 | 0.190 |
Why?
| | Pregnancy | 8 | 2015 | 5671 | 0.190 |
Why?
| | Adolescent | 14 | 2021 | 18364 | 0.190 |
Why?
| | Animals | 25 | 2016 | 33152 | 0.190 |
Why?
| | Virus Shedding | 2 | 2011 | 41 | 0.190 |
Why?
| | Feces | 4 | 1990 | 392 | 0.190 |
Why?
| | Gastrointestinal Tract | 1 | 2022 | 174 | 0.180 |
Why?
| | Hospitalization | 5 | 2023 | 1778 | 0.180 |
Why?
| | Protease Inhibitors | 1 | 2020 | 101 | 0.180 |
Why?
| | Salivary Glands | 2 | 1997 | 32 | 0.180 |
Why?
| | Cells, Cultured | 7 | 2015 | 4044 | 0.180 |
Why?
| | B-Lymphocyte Subsets | 1 | 2000 | 67 | 0.180 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 7 | 2010 | 817 | 0.170 |
Why?
| | Lymphocyte Subsets | 2 | 2014 | 75 | 0.170 |
Why?
| | Phagocytes | 1 | 1999 | 90 | 0.170 |
Why?
| | Antiretroviral Therapy, Highly Active | 5 | 2010 | 258 | 0.170 |
Why?
| | Influenza B virus | 2 | 2009 | 34 | 0.170 |
Why?
| | Cross Infection | 2 | 1999 | 204 | 0.170 |
Why?
| | Coinfection | 1 | 2020 | 119 | 0.170 |
Why?
| | Africa | 2 | 2017 | 99 | 0.160 |
Why?
| | Influenza A virus | 2 | 2009 | 90 | 0.160 |
Why?
| | Veterans | 2 | 2022 | 1212 | 0.160 |
Why?
| | Nuclear Family | 1 | 1998 | 54 | 0.160 |
Why?
| | Nitric Oxide | 2 | 2008 | 891 | 0.160 |
Why?
| | Klebsiella Infections | 1 | 1998 | 23 | 0.160 |
Why?
| | Cholera | 1 | 1997 | 8 | 0.160 |
Why?
| | Risk Factors | 8 | 2016 | 8958 | 0.160 |
Why?
| | Klebsiella pneumoniae | 1 | 1998 | 39 | 0.160 |
Why?
| | Syndecan-1 | 1 | 2017 | 30 | 0.160 |
Why?
| | RNA, Viral | 5 | 2012 | 568 | 0.150 |
Why?
| | Immunophenotyping | 1 | 2018 | 276 | 0.150 |
Why?
| | Endocarditis, Bacterial | 1 | 1998 | 37 | 0.150 |
Why?
| | Candidiasis | 2 | 1995 | 59 | 0.150 |
Why?
| | Child, Preschool | 10 | 2013 | 9448 | 0.150 |
Why?
| | Mucus | 1 | 2017 | 54 | 0.150 |
Why?
| | Pharynx | 2 | 1998 | 52 | 0.150 |
Why?
| | Amino Acid Motifs | 2 | 2017 | 200 | 0.150 |
Why?
| | Disease Susceptibility | 2 | 2017 | 330 | 0.150 |
Why?
| | Paranasal Sinuses | 1 | 2017 | 64 | 0.150 |
Why?
| | Antigens, Bacterial | 3 | 2007 | 116 | 0.150 |
Why?
| | Lymphopoiesis | 1 | 2017 | 23 | 0.150 |
Why?
| | Neutralization Tests | 2 | 2013 | 64 | 0.150 |
Why?
| | Disease Models, Animal | 3 | 2016 | 3676 | 0.150 |
Why?
| | Receptors, CCR5 | 1 | 2017 | 54 | 0.150 |
Why?
| | CD4 Lymphocyte Count | 7 | 2010 | 261 | 0.150 |
Why?
| | Nitric Oxide Synthase | 1 | 1997 | 226 | 0.150 |
Why?
| | Monocytes | 2 | 2000 | 511 | 0.150 |
Why?
| | Cell Communication | 1 | 2018 | 279 | 0.150 |
Why?
| | Intestine, Small | 1 | 1997 | 130 | 0.140 |
Why?
| | Treatment Outcome | 5 | 2022 | 9319 | 0.140 |
Why?
| | Lung | 3 | 2012 | 3623 | 0.140 |
Why?
| | United States | 6 | 2023 | 12488 | 0.140 |
Why?
| | Nasal Mucosa | 2 | 2014 | 97 | 0.140 |
Why?
| | Aged, 80 and over | 7 | 2008 | 6541 | 0.140 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 1995 | 20 | 0.140 |
Why?
| | Gastrointestinal Diseases | 3 | 2001 | 186 | 0.140 |
Why?
| | Critical Illness | 2 | 2018 | 661 | 0.140 |
Why?
| | Plasma | 2 | 2012 | 194 | 0.130 |
Why?
| | Mice | 7 | 2016 | 15446 | 0.130 |
Why?
| | Prevalence | 3 | 2017 | 2321 | 0.130 |
Why?
| | Virulence Factors | 1 | 2017 | 142 | 0.130 |
Why?
| | Protective Factors | 1 | 2015 | 90 | 0.130 |
Why?
| | Measles | 1 | 1995 | 39 | 0.130 |
Why?
| | Time Factors | 11 | 2012 | 6368 | 0.130 |
Why?
| | Pregnancy Trimester, First | 1 | 2015 | 126 | 0.130 |
Why?
| | Blood Cells | 1 | 2014 | 39 | 0.130 |
Why?
| | Clostridium | 1 | 1994 | 15 | 0.130 |
Why?
| | Adjuvants, Immunologic | 1 | 2016 | 207 | 0.130 |
Why?
| | DNA, Bacterial | 3 | 2012 | 313 | 0.130 |
Why?
| | Intestinal Diseases, Parasitic | 3 | 1989 | 11 | 0.130 |
Why?
| | Type C Phospholipases | 1 | 1994 | 66 | 0.120 |
Why?
| | Antibodies, Viral | 2 | 2009 | 538 | 0.120 |
Why?
| | Complementarity Determining Regions | 1 | 2014 | 45 | 0.120 |
Why?
| | B-Cell Maturation Antigen | 1 | 2013 | 3 | 0.120 |
Why?
| | Clostridium Infections | 1 | 1994 | 57 | 0.120 |
Why?
| | Mutation Rate | 1 | 2014 | 25 | 0.120 |
Why?
| | Carrier State | 2 | 2015 | 57 | 0.120 |
Why?
| | Immunoglobulin Class Switching | 1 | 2013 | 15 | 0.120 |
Why?
| | Blood Proteins | 1 | 2015 | 240 | 0.120 |
Why?
| | Retrospective Studies | 3 | 2023 | 12929 | 0.120 |
Why?
| | Immunization, Secondary | 2 | 2010 | 83 | 0.120 |
Why?
| | Cell Line | 4 | 2007 | 2693 | 0.120 |
Why?
| | Maternal-Fetal Exchange | 1 | 2014 | 156 | 0.120 |
Why?
| | Chronic Disease | 2 | 2017 | 1630 | 0.120 |
Why?
| | Blood Bactericidal Activity | 3 | 1999 | 36 | 0.110 |
Why?
| | Phagocytosis | 2 | 2013 | 360 | 0.110 |
Why?
| | Cytidine Deaminase | 1 | 2013 | 57 | 0.110 |
Why?
| | Predictive Value of Tests | 4 | 2008 | 1857 | 0.110 |
Why?
| | Sequence Alignment | 1 | 2013 | 334 | 0.110 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 275 | 0.110 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 191 | 0.110 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1992 | 24 | 0.110 |
Why?
| | Cell Count | 1 | 2013 | 315 | 0.110 |
Why?
| | Nevirapine | 1 | 2012 | 14 | 0.110 |
Why?
| | Burkina Faso | 1 | 2012 | 3 | 0.110 |
Why?
| | Cytoplasm | 1 | 2013 | 269 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2021 | 1159 | 0.110 |
Why?
| | Amino Acid Sequence | 2 | 2013 | 2063 | 0.110 |
Why?
| | Cell Movement | 1 | 2017 | 888 | 0.110 |
Why?
| | Agglutination | 2 | 2014 | 5 | 0.110 |
Why?
| | Saliva | 4 | 2011 | 187 | 0.110 |
Why?
| | Pneumonia | 1 | 1997 | 579 | 0.110 |
Why?
| | Mammary Glands, Human | 1 | 2012 | 59 | 0.100 |
Why?
| | Premature Birth | 1 | 2015 | 284 | 0.100 |
Why?
| | Genes, Bacterial | 1 | 2012 | 161 | 0.100 |
Why?
| | Hydrogen Peroxide | 1 | 1993 | 302 | 0.100 |
Why?
| | HIV Envelope Protein gp120 | 2 | 2013 | 57 | 0.100 |
Why?
| | Structure-Activity Relationship | 2 | 2007 | 522 | 0.100 |
Why?
| | Child | 7 | 2023 | 19033 | 0.100 |
Why?
| | Inflammation | 2 | 2021 | 2545 | 0.100 |
Why?
| | Morphogenesis | 1 | 2012 | 166 | 0.100 |
Why?
| | Adenovirus Infections, Human | 1 | 1991 | 14 | 0.100 |
Why?
| | Lactation | 1 | 2012 | 156 | 0.100 |
Why?
| | DNA Fingerprinting | 1 | 1991 | 26 | 0.100 |
Why?
| | Staphylococcal Infections | 1 | 2015 | 348 | 0.100 |
Why?
| | Pseudomonas | 1 | 1991 | 27 | 0.100 |
Why?
| | Viruses | 1 | 2012 | 96 | 0.100 |
Why?
| | Proteinase Inhibitory Proteins, Secretory | 3 | 2001 | 3 | 0.100 |
Why?
| | Secretory Leukocyte Peptidase Inhibitor | 3 | 2001 | 6 | 0.100 |
Why?
| | Mothers | 1 | 2017 | 675 | 0.100 |
Why?
| | Staphylococcus aureus | 2 | 2015 | 394 | 0.100 |
Why?
| | Virulence | 4 | 1997 | 239 | 0.100 |
Why?
| | Enterocolitis | 1 | 1991 | 32 | 0.100 |
Why?
| | Pulmonary Alveoli | 1 | 1993 | 375 | 0.100 |
Why?
| | Immunization | 4 | 2005 | 412 | 0.090 |
Why?
| | RNA, Messenger | 2 | 2013 | 2657 | 0.090 |
Why?
| | Exercise | 1 | 2021 | 1647 | 0.090 |
Why?
| | Mucous Membrane | 1 | 2011 | 112 | 0.090 |
Why?
| | Virus Diseases | 3 | 1992 | 197 | 0.090 |
Why?
| | Epithelial Cells | 3 | 2008 | 951 | 0.090 |
Why?
| | Tetanus Toxoid | 2 | 2005 | 37 | 0.090 |
Why?
| | Child Day Care Centers | 1 | 1990 | 34 | 0.090 |
Why?
| | Gastrointestinal Microbiome | 1 | 2016 | 538 | 0.090 |
Why?
| | Infant, Premature | 1 | 2013 | 479 | 0.090 |
Why?
| | Research | 2 | 2010 | 406 | 0.090 |
Why?
| | alpha 1-Antitrypsin | 1 | 2010 | 111 | 0.090 |
Why?
| | Suicide | 1 | 2015 | 496 | 0.090 |
Why?
| | Double-Blind Method | 2 | 2012 | 1683 | 0.090 |
Why?
| | Geriatrics | 1 | 2010 | 67 | 0.090 |
Why?
| | Pseudomonas Infections | 1 | 1991 | 193 | 0.090 |
Why?
| | Immunity, Herd | 1 | 2008 | 6 | 0.090 |
Why?
| | Recombinant Proteins | 2 | 2007 | 1302 | 0.080 |
Why?
| | Lipids | 2 | 2007 | 591 | 0.080 |
Why?
| | Models, Molecular | 3 | 2020 | 1434 | 0.080 |
Why?
| | Phenotype | 1 | 2017 | 2937 | 0.080 |
Why?
| | Anti-Infective Agents | 2 | 2004 | 227 | 0.080 |
Why?
| | C-Reactive Protein | 2 | 2008 | 364 | 0.080 |
Why?
| | Phylogeny | 1 | 2012 | 817 | 0.080 |
Why?
| | Base Sequence | 1 | 2012 | 2148 | 0.080 |
Why?
| | Virus Integration | 1 | 2008 | 71 | 0.080 |
Why?
| | Evidence-Based Practice | 1 | 2010 | 193 | 0.080 |
Why?
| | Child Development | 1 | 2012 | 402 | 0.080 |
Why?
| | Androstadienes | 1 | 2008 | 95 | 0.080 |
Why?
| | Opportunistic Infections | 4 | 1992 | 44 | 0.080 |
Why?
| | Botswana | 1 | 2007 | 8 | 0.080 |
Why?
| | Campylobacter jejuni | 1 | 2007 | 11 | 0.080 |
Why?
| | Coccidia | 1 | 1987 | 1 | 0.080 |
Why?
| | Immunoassay | 1 | 2008 | 101 | 0.080 |
Why?
| | Cytomegalovirus Infections | 1 | 1990 | 187 | 0.080 |
Why?
| | Salivary Proteins and Peptides | 2 | 1997 | 10 | 0.080 |
Why?
| | Interleukin-6 | 3 | 2021 | 685 | 0.080 |
Why?
| | Haemophilus influenzae | 1 | 2007 | 50 | 0.080 |
Why?
| | Helicobacter pylori | 1 | 2007 | 31 | 0.080 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2008 | 112 | 0.080 |
Why?
| | Urinalysis | 1 | 2007 | 68 | 0.080 |
Why?
| | Antigens, Viral | 1 | 2008 | 178 | 0.070 |
Why?
| | Serine Proteinase Inhibitors | 2 | 1997 | 35 | 0.070 |
Why?
| | Keratinocytes | 1 | 2008 | 227 | 0.070 |
Why?
| | Prednisone | 1 | 1987 | 235 | 0.070 |
Why?
| | Sepsis | 1 | 1993 | 531 | 0.070 |
Why?
| | Methotrexate | 1 | 1987 | 227 | 0.070 |
Why?
| | Zidovudine | 2 | 2004 | 77 | 0.070 |
Why?
| | HIV | 1 | 2007 | 209 | 0.070 |
Why?
| | Bronchodilator Agents | 1 | 2008 | 251 | 0.070 |
Why?
| | Ileum | 2 | 1997 | 100 | 0.070 |
Why?
| | Neuralgia | 1 | 1987 | 120 | 0.070 |
Why?
| | Endothelium, Vascular | 1 | 1992 | 890 | 0.070 |
Why?
| | HTLV-II Infections | 1 | 2005 | 2 | 0.070 |
Why?
| | Rabbits | 2 | 1997 | 779 | 0.060 |
Why?
| | Secretory Component | 1 | 2004 | 1 | 0.060 |
Why?
| | Neuraminidase | 1 | 2004 | 24 | 0.060 |
Why?
| | N-Acetylneuraminic Acid | 1 | 2004 | 9 | 0.060 |
Why?
| | Lactoferrin | 1 | 2004 | 28 | 0.060 |
Why?
| | Smallpox Vaccine | 1 | 2003 | 23 | 0.060 |
Why?
| | Herpes Zoster | 1 | 1987 | 334 | 0.060 |
Why?
| | Signal Transduction | 1 | 2016 | 4688 | 0.060 |
Why?
| | Hemolysis | 2 | 1994 | 171 | 0.060 |
Why?
| | Acute Disease | 2 | 1995 | 933 | 0.050 |
Why?
| | Kinetics | 2 | 1997 | 1623 | 0.050 |
Why?
| | Complement Activation | 2 | 1996 | 344 | 0.050 |
Why?
| | Colony Count, Microbial | 2 | 2014 | 120 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2022 | 80 | 0.050 |
Why?
| | Molecular Weight | 2 | 1995 | 340 | 0.050 |
Why?
| | Respiratory Tract Infections | 1 | 2005 | 329 | 0.050 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 36 | 0.050 |
Why?
| | Macrophages | 2 | 1999 | 1311 | 0.050 |
Why?
| | Protozoan Infections | 3 | 1992 | 10 | 0.050 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 79 | 0.050 |
Why?
| | Pregnancy Trimester, Third | 1 | 2001 | 69 | 0.050 |
Why?
| | Vitamin A | 1 | 2001 | 55 | 0.050 |
Why?
| | Dysbiosis | 1 | 2022 | 148 | 0.050 |
Why?
| | Respiratory Mucosa | 1 | 2003 | 252 | 0.050 |
Why?
| | Bacterial Typing Techniques | 2 | 2010 | 43 | 0.050 |
Why?
| | Thailand | 2 | 1990 | 10 | 0.050 |
Why?
| | Biocatalysis | 1 | 2020 | 64 | 0.050 |
Why?
| | Interphase | 1 | 2000 | 30 | 0.050 |
Why?
| | State Medicine | 1 | 1980 | 20 | 0.050 |
Why?
| | Lymphocyte Count | 1 | 2000 | 135 | 0.050 |
Why?
| | Blood | 2 | 2004 | 97 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 748 | 0.050 |
Why?
| | Cryoelectron Microscopy | 1 | 2020 | 142 | 0.050 |
Why?
| | Catalytic Domain | 1 | 2020 | 206 | 0.050 |
Why?
| | Macrophage-1 Antigen | 1 | 1999 | 28 | 0.040 |
Why?
| | Gene Products, nef | 1 | 1999 | 13 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 168 | 0.040 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1999 | 25 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2022 | 625 | 0.040 |
Why?
| | Smoking | 1 | 2007 | 1478 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2004 | 964 | 0.040 |
Why?
| | Drug Interactions | 1 | 2001 | 351 | 0.040 |
Why?
| | Multigene Family | 1 | 2000 | 200 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2008 | 1130 | 0.040 |
Why?
| | Metabolic Diseases | 2 | 2012 | 103 | 0.040 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 1998 | 61 | 0.040 |
Why?
| | Public Health | 1 | 2003 | 447 | 0.040 |
Why?
| | Chemotaxis | 1 | 1999 | 135 | 0.040 |
Why?
| | Colorado | 3 | 1997 | 4178 | 0.040 |
Why?
| | Gene Frequency | 1 | 2000 | 511 | 0.040 |
Why?
| | Survival Analysis | 3 | 2014 | 1262 | 0.040 |
Why?
| | DNA Restriction Enzymes | 1 | 1998 | 53 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 3 | 2009 | 504 | 0.040 |
Why?
| | Exudates and Transudates | 1 | 1998 | 14 | 0.040 |
Why?
| | Quality Control | 1 | 1998 | 155 | 0.040 |
Why?
| | Molsidomine | 1 | 1997 | 5 | 0.040 |
Why?
| | Dihydrolipoamide Dehydrogenase | 1 | 1997 | 7 | 0.040 |
Why?
| | Vibrio cholerae | 1 | 1997 | 8 | 0.040 |
Why?
| | Cholera Toxin | 1 | 1997 | 28 | 0.040 |
Why?
| | Peru | 1 | 1997 | 59 | 0.040 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2019 | 240 | 0.040 |
Why?
| | Bacteriological Techniques | 1 | 1998 | 66 | 0.040 |
Why?
| | Nitrites | 1 | 1997 | 80 | 0.040 |
Why?
| | Ligands | 1 | 2019 | 565 | 0.040 |
Why?
| | Jejunum | 1 | 1997 | 30 | 0.040 |
Why?
| | Muscle, Smooth | 1 | 1997 | 157 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 1999 | 695 | 0.040 |
Why?
| | Cause of Death | 2 | 2014 | 379 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 1997 | 301 | 0.040 |
Why?
| | Catalysis | 1 | 2017 | 295 | 0.030 |
Why?
| | Reference Values | 1 | 1997 | 770 | 0.030 |
Why?
| | Cell Separation | 1 | 1997 | 293 | 0.030 |
Why?
| | Antibiosis | 1 | 2015 | 7 | 0.030 |
Why?
| | Streptococcus mitis | 1 | 2015 | 8 | 0.030 |
Why?
| | Lactobacillus | 1 | 2015 | 23 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 212 | 0.030 |
Why?
| | Antibody-Producing Cells | 1 | 1995 | 29 | 0.030 |
Why?
| | Age Factors | 2 | 1995 | 2990 | 0.030 |
Why?
| | Antigen-Antibody Reactions | 1 | 1995 | 50 | 0.030 |
Why?
| | Hypokalemia | 1 | 1995 | 31 | 0.030 |
Why?
| | Kenya | 1 | 1995 | 100 | 0.030 |
Why?
| | Drug Tolerance | 1 | 1995 | 78 | 0.030 |
Why?
| | Catalase | 1 | 2015 | 122 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 1995 | 37 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 1996 | 404 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1995 | 197 | 0.030 |
Why?
| | Potassium | 1 | 1995 | 132 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 2010 | 1379 | 0.030 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 1995 | 69 | 0.030 |
Why?
| | Gas Gangrene | 1 | 1994 | 1 | 0.030 |
Why?
| | Complement C5 | 1 | 1995 | 74 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 1969 | 0.030 |
Why?
| | Immunocompetence | 1 | 1994 | 43 | 0.030 |
Why?
| | Cerebrospinal Fluid Otorrhea | 1 | 2014 | 5 | 0.030 |
Why?
| | Syndrome | 1 | 1995 | 343 | 0.030 |
Why?
| | Transforming Growth Factor beta | 2 | 1994 | 461 | 0.030 |
Why?
| | Cell Growth Processes | 1 | 2014 | 53 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 1993 | 1082 | 0.030 |
Why?
| | Neutrophils | 1 | 1999 | 1142 | 0.030 |
Why?
| | Duodenum | 1 | 1994 | 67 | 0.030 |
Why?
| | Immune Evasion | 1 | 2014 | 47 | 0.030 |
Why?
| | South Africa | 1 | 2014 | 163 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2014 | 4887 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 1997 | 817 | 0.030 |
Why?
| | Pilot Projects | 1 | 1998 | 1405 | 0.030 |
Why?
| | Creatinine | 1 | 1995 | 491 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1338 | 0.030 |
Why?
| | Peptide Hydrolases | 1 | 2014 | 106 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 9 | 0.030 |
Why?
| | AIDS Vaccines | 1 | 2013 | 41 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2000 | 1746 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 1997 | 1681 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 1004 | 0.030 |
Why?
| | Mice, Knockout | 1 | 1998 | 2664 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 734 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2013 | 367 | 0.030 |
Why?
| | Measles Vaccine | 1 | 1991 | 17 | 0.030 |
Why?
| | Mammary Glands, Animal | 1 | 2012 | 122 | 0.030 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 1991 | 16 | 0.030 |
Why?
| | Milk | 1 | 2012 | 125 | 0.030 |
Why?
| | Vaccines | 1 | 1996 | 380 | 0.030 |
Why?
| | Species Specificity | 1 | 2013 | 559 | 0.030 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1991 | 25 | 0.020 |
Why?
| | Gastroenteritis | 2 | 1989 | 64 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2010 | 2659 | 0.020 |
Why?
| | Adenoviruses, Human | 1 | 1991 | 24 | 0.020 |
Why?
| | Rats | 2 | 2004 | 5339 | 0.020 |
Why?
| | Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2010 | 11 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1991 | 181 | 0.020 |
Why?
| | Diarrhea, Infantile | 1 | 1990 | 7 | 0.020 |
Why?
| | Qualitative Research | 1 | 2015 | 952 | 0.020 |
Why?
| | Institutionalization | 1 | 1990 | 12 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2010 | 69 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2010 | 121 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2000 | 2435 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 1896 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2011 | 4521 | 0.020 |
Why?
| | Health Planning Guidelines | 1 | 2010 | 25 | 0.020 |
Why?
| | Interleukin-17 | 1 | 2010 | 105 | 0.020 |
Why?
| | DNA, Ribosomal | 1 | 2010 | 79 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 142 | 0.020 |
Why?
| | Sex Factors | 1 | 1995 | 1765 | 0.020 |
Why?
| | Cell Survival | 1 | 1993 | 1045 | 0.020 |
Why?
| | Nasal Cavity | 1 | 2010 | 47 | 0.020 |
Why?
| | Mental Health | 1 | 2015 | 566 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2012 | 418 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2012 | 804 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 216 | 0.020 |
Why?
| | Sampling Studies | 1 | 1990 | 91 | 0.020 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2009 | 37 | 0.020 |
Why?
| | Health | 1 | 2010 | 80 | 0.020 |
Why?
| | Staphylococcus epidermidis | 1 | 2010 | 70 | 0.020 |
Why?
| | Proteomics | 1 | 2015 | 850 | 0.020 |
Why?
| | Antigen-Presenting Cells | 1 | 2010 | 156 | 0.020 |
Why?
| | Counterimmunoelectrophoresis | 1 | 1989 | 2 | 0.020 |
Why?
| | Cattle | 1 | 1992 | 974 | 0.020 |
Why?
| | Cross Reactions | 1 | 1989 | 116 | 0.020 |
Why?
| | Colon | 1 | 1991 | 237 | 0.020 |
Why?
| | False Positive Reactions | 1 | 1989 | 115 | 0.020 |
Why?
| | Homosexuality | 1 | 1988 | 16 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 1998 | 4574 | 0.020 |
Why?
| | Immunization Schedule | 1 | 2010 | 187 | 0.020 |
Why?
| | Palatine Tonsil | 1 | 2008 | 32 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2008 | 42 | 0.020 |
Why?
| | Virus Cultivation | 1 | 2008 | 25 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2008 | 135 | 0.020 |
Why?
| | Forecasting | 1 | 2010 | 348 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2010 | 251 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 623 | 0.020 |
Why?
| | Fluticasone | 1 | 2008 | 87 | 0.020 |
Why?
| | Kidney | 1 | 1995 | 1351 | 0.020 |
Why?
| | Hemophilia A | 1 | 1989 | 69 | 0.020 |
Why?
| | Nutritional Status | 1 | 1990 | 298 | 0.020 |
Why?
| | Specimen Handling | 1 | 1989 | 163 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2008 | 206 | 0.020 |
Why?
| | Telomere | 1 | 2010 | 204 | 0.020 |
Why?
| | Military Personnel | 1 | 1995 | 525 | 0.020 |
Why?
| | Albuterol | 1 | 2008 | 104 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2010 | 297 | 0.020 |
Why?
| | Immunity | 1 | 2008 | 129 | 0.020 |
Why?
| | Age Distribution | 1 | 2008 | 358 | 0.020 |
Why?
| | Recurrence | 1 | 2010 | 971 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2012 | 0.020 |
Why?
| | Spirometry | 1 | 2008 | 262 | 0.020 |
Why?
| | Disease Progression | 3 | 1999 | 2477 | 0.020 |
Why?
| | Cough | 1 | 2008 | 102 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2010 | 497 | 0.020 |
Why?
| | Virus Activation | 1 | 1987 | 77 | 0.020 |
Why?
| | Biopsy | 1 | 1991 | 1078 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2008 | 240 | 0.020 |
Why?
| | Health Resources | 1 | 2008 | 130 | 0.020 |
Why?
| | Antitubercular Agents | 1 | 2008 | 163 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 1989 | 322 | 0.020 |
Why?
| | ROC Curve | 1 | 2008 | 470 | 0.020 |
Why?
| | Inpatients | 1 | 2010 | 387 | 0.020 |
Why?
| | Fever | 1 | 2008 | 283 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2008 | 520 | 0.020 |
Why?
| | Biodiversity | 1 | 2010 | 376 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2008 | 652 | 0.020 |
Why?
| | Telomerase | 1 | 2008 | 207 | 0.020 |
Why?
| | Biomedical Research | 1 | 2012 | 600 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 1990 | 1469 | 0.020 |
Why?
| | Chemokine CCL5 | 1 | 2005 | 46 | 0.020 |
Why?
| | Liver Diseases | 1 | 2008 | 282 | 0.020 |
Why?
| | Least-Squares Analysis | 1 | 2005 | 72 | 0.020 |
Why?
| | Immune Tolerance | 1 | 1987 | 330 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2010 | 1237 | 0.020 |
Why?
| | Poverty | 1 | 2008 | 444 | 0.020 |
Why?
| | Perinatal Care | 1 | 2004 | 37 | 0.020 |
Why?
| | Nasopharynx | 1 | 2004 | 64 | 0.020 |
Why?
| | Kidney Diseases | 1 | 2008 | 439 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 4684 | 0.010 |
Why?
| | Drug Resistance, Viral | 1 | 2004 | 98 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2010 | 2491 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2005 | 605 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 764 | 0.010 |
Why?
| | Cuba | 1 | 1980 | 11 | 0.010 |
Why?
| | Occupational Health Services | 1 | 1980 | 31 | 0.010 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 1999 | 12 | 0.010 |
Why?
| | nef Gene Products, Human Immunodeficiency Virus | 1 | 1999 | 20 | 0.010 |
Why?
| | Chemokine CCL4 | 1 | 1999 | 21 | 0.010 |
Why?
| | Macaca | 1 | 1999 | 51 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 1999 | 108 | 0.010 |
Why?
| | Simian Immunodeficiency Virus | 1 | 1999 | 74 | 0.010 |
Why?
| | Encephalitis, Viral | 1 | 1999 | 42 | 0.010 |
Why?
| | Adenoviridae | 1 | 1999 | 191 | 0.010 |
Why?
| | Maternal Health Services | 1 | 1980 | 83 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 2000 | 649 | 0.010 |
Why?
| | Quinine | 1 | 1998 | 12 | 0.010 |
Why?
| | Deoxycholic Acid | 1 | 1998 | 20 | 0.010 |
Why?
| | Centrifugation | 1 | 1997 | 31 | 0.010 |
Why?
| | Proviruses | 1 | 1996 | 6 | 0.010 |
Why?
| | Didanosine | 1 | 1996 | 13 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2000 | 1124 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 1996 | 65 | 0.010 |
Why?
| | Mental Health Services | 1 | 1980 | 331 | 0.010 |
Why?
| | DNA, Viral | 1 | 1996 | 351 | 0.010 |
Why?
| | Nucleic Acids | 1 | 1995 | 58 | 0.010 |
Why?
| | Mitosis | 1 | 1995 | 172 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1997 | 1072 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1998 | 1787 | 0.010 |
Why?
| | Cell Nucleus | 1 | 1995 | 577 | 0.010 |
Why?
| | Vermont | 1 | 1989 | 7 | 0.010 |
Why?
| | Water Supply | 1 | 1989 | 71 | 0.010 |
Why?
| | Rural Population | 1 | 1989 | 451 | 0.000 |
Why?
|
|
Janoff's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|